Literature DB >> 23104851

Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia.

Manikandan Panchatcharam1, Sumitra Miriyala, Abdelghaffar Salous, Jessica Wheeler, Anping Dong, Paul Mueller, Manjula Sunkara, Diana Escalante-Alcalde, Andrew J Morris, Susan S Smyth.   

Abstract

OBJECTIVE: The lipid phosphate phosphatase 3 (LPP3) degrades bioactive lysophospholipids, including lysophosphatidic acid and sphingosine-1-phosphate, and thereby terminates their signaling effects. Although emerging evidence links lysophosphatidic acid to atherosclerosis and vascular injury responses, little is known about the role of vascular LPP3. The goal of this study was to determine the role of LPP3 in the development of vascular neointima formation and smooth muscle cells (SMC) responses. METHODS AND
RESULTS: We report that LPP3 is expressed in vascular SMC after experimental arterial injury. Using gain- and loss-of-function approaches, we establish that a major function of LPP3 in isolated SMC cells is to attenuate proliferation (extracellular signal-regulated kinases) activity, Rho activation, and migration in response to serum and lysophosphatidic acid. These effects are at least partially a consequence of LPP3-catalyzed lysophosphatidic acid hydrolysis. Mice with selective inactivation of LPP3 in SMC display an exaggerated neointimal response to injury.
CONCLUSIONS: Our observations suggest that LPP3 serves as an intrinsic negative regulator of SMC phenotypic modulation and inflammation after vascular injury, in part, by regulating lysophospholipid signaling. These findings may provide a mechanistic link to explain the association between a PPAP2B polymorphism and coronary artery disease risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104851      PMCID: PMC3524385          DOI: 10.1161/ATVBAHA.112.300527

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation.

Authors:  Utako Kaneyuki; Seiji Ueda; Sho-ichi Yamagishi; Seiya Kato; Toshiko Fujimura; Ryo Shibata; Ayako Hayashida; Junko Yoshimura; Masamichi Kojiro; Koichi Oshima; Seiya Okuda
Journal:  Vascul Pharmacol       Date:  2006-11-14       Impact factor: 5.773

2.  Mechanisms of lysophosphatidic acid-induced increase in intracellular calcium in vascular smooth muscle cells.

Authors:  Yan-Jun Xu; Harjot K Saini; Sukhinder K Cheema; Naranjan S Dhalla
Journal:  Cell Calcium       Date:  2005-10-10       Impact factor: 6.817

3.  High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice.

Authors:  John J Lepore; Lan Cheng; Min Min Lu; Patricia A Mericko; Edward E Morrisey; Michael S Parmacek
Journal:  Genesis       Date:  2005-04       Impact factor: 2.487

4.  Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform.

Authors:  Naotoshi Sugimoto; Noriko Takuwa; Hiroyuki Okamoto; Sotaro Sakurada; Yoh Takuwa
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

5.  Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.

Authors:  Venkateswaran Subramanian; Jonathan Golledge; Talha Ijaz; Dennis Bruemmer; Alan Daugherty
Journal:  Circ Res       Date:  2010-08-26       Impact factor: 17.367

6.  Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteries.

Authors:  Takuya Shimizu; Tatsu Nakazawa; Aesim Cho; Frank Dastvan; Dustin Shilling; Günter Daum; Michael A Reidy
Journal:  Circ Res       Date:  2007-09-13       Impact factor: 17.367

7.  Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells.

Authors:  Mi Jeong Lee; Eun Su Jeon; Jung Sub Lee; Mong Cho; Dong-Soo Suh; Chulhun L Chang; Jae Ho Kim
Journal:  J Cell Biochem       Date:  2008-05-15       Impact factor: 4.429

8.  Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia.

Authors:  Seema Khurana; Alok Tomar; Sudeep P George; Yaohong Wang; Mohammad Rizwan Siddiqui; Huazhang Guo; Gabor Tigyi; Sijo Mathew
Journal:  Exp Cell Res       Date:  2007-11-12       Impact factor: 3.905

9.  Generation of a conditional Ppap2b/Lpp3 null allele.

Authors:  Diana Escalante-Alcalde; Roberto Sánchez-Sánchez; Colin L Stewart
Journal:  Genesis       Date:  2007-07       Impact factor: 2.487

10.  Lysophosphatidic acid induces neointima formation through PPARgamma activation.

Authors:  Chunxiang Zhang; Daniel L Baker; Satoshi Yasuda; Natalia Makarova; Louisa Balazs; Leonard R Johnson; Gopal K Marathe; Thomas M McIntyre; Yong Xu; Glenn D Prestwich; Hoe-Sup Byun; Robert Bittman; Gabor Tigyi
Journal:  J Exp Med       Date:  2004-03-08       Impact factor: 14.307

View more
  28 in total

Review 1.  Lysophospholipids in coronary artery and chronic ischemic heart disease.

Authors:  Ahmed Abdel-Latif; Paula M Heron; Andrew J Morris; Susan S Smyth
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

2.  Regulation of PLPP3 gene expression by NF-κB family transcription factors.

Authors:  Guogen Mao; Susan S Smyth; Andrew J Morris
Journal:  J Biol Chem       Date:  2019-07-30       Impact factor: 5.157

3.  Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.

Authors:  Mohamad Navab; Arnab Chattopadhyay; Greg Hough; David Meriwether; Spencer I Fogelman; Alan C Wagner; Victor Grijalva; Feng Su; G M Anantharamaiah; Lin H Hwang; Kym F Faull; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2015-02-02       Impact factor: 5.922

Review 4.  Lipid phosphate phosphatases and their roles in mammalian physiology and pathology.

Authors:  Xiaoyun Tang; Matthew G K Benesch; David N Brindley
Journal:  J Lipid Res       Date:  2015-03-26       Impact factor: 5.922

5.  Lysophosphatidic acid and cardiovascular disease: seeing is believing.

Authors:  Andrew J Morris; Susan S Smyth
Journal:  J Lipid Res       Date:  2013-03-18       Impact factor: 5.922

6.  Lipid phosphate phosphatases: more than one way to put the brakes on LPA signaling?

Authors:  Andrew J Morris; Susan S Smyth
Journal:  J Lipid Res       Date:  2014-09-30       Impact factor: 5.922

Review 7.  Lysophospholipid mediators in the vasculature.

Authors:  Paul Mueller; Shaojing Ye; Andrew Morris; Susan S Smyth
Journal:  Exp Cell Res       Date:  2015-03-28       Impact factor: 3.905

8.  Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome.

Authors:  Makoto Kurano; Kuniyuki Kano; Tomotaka Dohi; Hirotaka Matsumoto; Koji Igarashi; Masako Nishikawa; Ryunosuke Ohkawa; Hitoshi Ikeda; Katsumi Miyauchi; Hiroyuki Daida; Junken Aoki; Yutaka Yatomi
Journal:  J Lipid Res       Date:  2016-12-22       Impact factor: 5.922

9.  Arterial smooth muscle.

Authors:  Valerie Z Wall; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10       Impact factor: 8.311

10.  Role of lipid phosphate phosphatase 3 in human aortic endothelial cell function.

Authors:  Zahia Touat-Hamici; Henri Weidmann; Yuna Blum; Carole Proust; Hervé Durand; Francesca Iannacci; Veronica Codoni; Pauline Gaignard; Patrice Thérond; Mete Civelek; Sonia A Karabina; Aldons J Lusis; François Cambien; Ewa Ninio
Journal:  Cardiovasc Res       Date:  2016-09-30       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.